Bosh sahifaSTRO • NASDAQ
add
Sutro Biopharma Inc
0,80 $
Seans yopilganidan keyin:(1,46%)+0,012
0,81 $
Yopilgan:26-iyn, 18:13:11 (GMT-4) · USD · NASDAQ · Ogohlantirish
Yopilish kursi
0,81 $
Kunlik diapazon
0,77 $ - 0,84 $
Yillik diapazon
0,52 $ - 5,17 $
Bozor kapitalizatsiyasi
67,09 mln USD
Oʻrtacha hajm
872,19 ming
Narx/foyda
-
Dividend daromadliligi
-
Asosiy maydon
NASDAQ
Yangiliklarda
Moliyaviy axborot
Moliyaviy hisobot
Daromad
Sof foyda
| (USD) | mar, 2025info | Y/Y qiyosi |
|---|---|---|
Daromad | 17,40 mln | 33,76% |
Joriy xarajat | 62,59 mln | -5,78% |
Sof foyda | -75,97 mln | -30,50% |
Sof foyda marjasi | -436,62 | 2,44% |
Har bir ulushga tushum | -0,80 | 9,92% |
EBITDA | -45,57 mln | 16,89% |
Amaldagi soliq stavkasi | — | — |
Balans
Jami aktivlari
Jami passivlari
| (USD) | mar, 2025info | Y/Y qiyosi |
|---|---|---|
Naqd pul va qisqa investitsiyalar | 248,97 mln | -20,51% |
Jami aktivlari | 321,43 mln | -20,32% |
Jami passivlari | 347,24 mln | 13,71% |
Umumiy kapital | -25,81 mln | — |
Tarqatilgan aksiyalar | 84,46 mln | — |
Narxi/balansdagi bahosi | -2,60 | — |
Aktivlardan daromad | -33,49% | — |
Kapitaldan daromad | -374,73% | — |
Pul aylanmasi
Naqd pulning sof oʻzgarishi
| (USD) | mar, 2025info | Y/Y qiyosi |
|---|---|---|
Sof foyda | -75,97 mln | -30,50% |
Operatsiyalardan naqd pul | -67,88 mln | -4,85% |
Sarmoyadan naqd pul | -16,26 mln | -125,36% |
Moliyadan naqd pul | 66,00 ming | 101,92% |
Naqd pulning sof oʻzgarishi | -84,08 mln | -1 968,27% |
Boʻsh pul | -41,21 mln | -3,73% |
Haqida
Sutro Biopharma, Inc. is a publicly traded biotechnology company headquartered in South San Francisco, California focused on clinical-stage drug discovery, development and manufacturing. Using a proprietary cell-free protein synthesis platform, Sutro is working on oncology therapeutics using protein engineering and rational design. Founded in 2003 under the name Fundamental Applied Biology, the company name changed to Sutro Biopharma in 2009. William Newell, CEO as of 2024, joined Sutro in January 2009.
Sutro's cell-free protein synthesis and site-specific conjugation platform, XpressCF+, contributed to the discovery of STRO-001 and STRO-002, internally-developed antibody drug conjugates, or ADCs. STRO-001 is an ADC targeting CD74, a protein highly expressed in multiple myeloma and non-Hodgkin's lymphoma, and is currently in a Phase I clinical trial. STRO-002 is an ADC targeting folate receptor alpha, a cell-surface protein highly expressed in gynecological cancers. Wikipedia
Tashkil etilgan
2003
Sayt
Xodimlar soni
269
